- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00216034
Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK
June 6, 2016 updated by: Takashi Fujimura, Hokuriku-Kinki Immunochemotherapy Study Group
Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy
A randomized controlled study is conducted on patients with resected gastric cancer assigned to postoperative adjuvant therapy of TS-1 alone or PSK combined with TS-1, with the objective to examine or validate the outcome, QOL and prognostic factors (host and tumor factors), and explore the factors enhancing the antitumor effect of TS-1.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The 5-year survival after gastric cancer surgery remains poor as the cancer advances to stages II, IIIA, IIIB and IV.
Tegafur-gimeracil-oteracil potassium (TS-1) is used as the first line treatment for advanced and recurrent gastric cancer.
But TS-1 is accompanied by an adverse drug reaction of bone marrow suppression that is not readily seen in conventional oral fluoropyrimidines.
Among randomized controlled trials on postoperative adjuvant chemotherapy for gastric cancer, the beneficial results of survival rates using Krestin (PSK) in combination with chemotherapy have been reported.
With the objective to enhance the antitumor effect of TS-1 and to improve the QOL of patients, we have planned to validate the clinical significance of combined PSK and TS-1 therapy as postoperative adjuvant therapy for gastric cancer, using in principle the TS-1 regimen of 2-week dosing 1-week off for 6 months followed by 2-week dosing 2-week off for 6 months.
Study Type
Interventional
Enrollment (Actual)
255
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fukui, Japan, 910-0833
- Fukui Cardio Vascular Center
-
Fukui, Japan, 910-8561
- Fukui General Hospital
-
Fukui, Japan, 918-8503
- Fukui Saiseikai Hospital
-
Gifu, Japan, 500-8717
- Gifu Prefectural General Medical Center
-
Gifu, Japan, 500-8513
- Gifu Municipal Hospital
-
Gifu, Japan, 501-1194
- Gifu University Hospital
-
Kyoto, Japan, 602-8566
- University Hospital, Kyoto Prefectural University of Medicine
-
Kyoto, Japan, 605-0981
- Kyoto First Red Cross Hospital
-
Kyoto, Japan, 602-8800
- Nishijin Hospital
-
Nara, Japan, 630-8305
- Nara City Hospital
-
Osaka, Japan, 545-0053
- Osaka Railway hospital
-
Toyama, Japan, 930-8550
- Toyama Prefectural Central Hospital
-
-
Fukui
-
Eiheiji, Fukui, Japan, 910-1193
- University of Fukui Hospital
-
Tsuruga, Fukui, Japan, 914-0195
- National Hospital Organization Fukui Hospital
-
-
Hyogo
-
Kobe, Hyogo, Japan, 651-1145
- Shakaihoken Kobe Central Hospital
-
-
Ishikawa
-
Hakusan, Ishikawa, Japan, 924-8588
- Public Central Hospital of Matto Ishikawa
-
Kanazawa, Ishikawa, Japan, 920-8530
- Ishikawa Prefectural Central Hospital
-
Kanazawa, Ishikawa, Japan, 920-0934
- Kanazawa University Hospital
-
Kanazawa, Ishikawa, Japan, 921-8162
- Kanazawa Redcross Hospital
-
Uchinada, Ishikawa, Japan, 920-0293
- Kanazawa Medical University Hospital
-
-
Kyoto
-
Fukuchiyama, Kyoto, Japan, 620-8505
- Fukuchiyama City Hospital
-
Fushimi, Kyoto, Japan, 612-8364
- Kyoto Ohashi General Hospital
-
Joyo, Kyoto, Japan, 610-0121
- Houyu hospital
-
Maizuru, Kyoto, Japan, 625-8502
- National Hospital Organization Maizuru Medical Center
-
Nagaokakyo, Kyoto, Japan, 617-0814
- Saiseikai Kyoto Hospital
-
Nantan, Kyoto, Japan, 629-0197
- Nantan General Hospital
-
Uji, Kyoto, Japan, 611-0001
- Rokujizo Hospital
-
Uji, Kyoto, Japan, 611-0025
- Second Okamoto General Hospital
-
Yosano, Kyoto, Japan, 629-2261
- Kyoto Prefectural Yosanoumi Hospital
-
-
Nakagyou-ku Kyoto
-
Nishinokyokurumazaka-cho, Nakagyou-ku Kyoto, Japan, 604-8405
- Marutamachi Hospital
-
-
Osaka
-
Moriguchi, Osaka, Japan, 570-8540
- Matsushita Memorial Hospital
-
Takatsuki, Osaka, Japan, 569-1121
- Midorigaoka Hospital
-
-
Osaka Abeno-ku
-
Asahi-machi, Osaka Abeno-ku, Japan, 545-8586
- Osaka City University Hospital
-
-
Osaka Kita-ku
-
Nakanoshima, Osaka Kita-ku, Japan, 530-0005
- Sumitomo Hospital
-
-
Shiga
-
Otsu, Shiga, Japan, 520-2192
- Shiga University Of Medical Science Hospital
-
Ritto, Shiga, Japan, 520-3040
- Saiseikai Shigaken Hospital
-
-
Shimane
-
Izumo, Shimane, Japan, 693-8501
- Shimane University Hospital
-
-
Toyama
-
Takaoka, Toyama, Japan, 933-8525
- Saiseikai Takaoka Hospital
-
Takaoka, Toyama, Japan, 933-8555
- Kouseiren Takaoka Hoapital
-
Uozu, Toyama, Japan, 937-0042
- Toyama Rosai Hospital
-
Yatsuo, Toyama, Japan, 939-2376
- Yatsuo General Hospital
-
-
Wakayama
-
Gobou, Wakayama, Japan, 644-0011
- Kitade Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with microscopic stage II or IIIA resectable gastric cancer
- Patients who have not received preoperative cancer therapy (radiotherapy, chemotherapy or immunotherapy)
- Patients with serum immunosuppressive acidic protein (IAP) measured within 2 weeks before surgery
- Patients with no metachronous or synchronous multiple cancer
- Patients without severe impairment of renal, hepatic and bone marrow functions
- Patients who are judged to be capable of tolerating surgery
- Patients with preoperative performance status 0 to 2
- Patients with no serious concurrent complications (such as bone marrow suppression, diarrhea and infection)
- Patients who are judged to be capable of tolerating this treatment, and who have given written informed consent to participate in this study
Exclusion Criteria:
- Patients with fresh hemorrhage from the gastrointestinal tract
- Patients with retention of body fluid necessitating treatment
- Patients with infection, intestinal palsy or intestinal occlusion
- Patients who are pregnant or hope to become pregnant during the study period
- Patients with diabetes treated by continuous use of insulin or showing poor glycemic control
- Patients with a history of ischemic heart disease
- Patients with concurrent psychiatric disease or psychotic symptoms, and judged to have difficulties participating in the study
- Patients receiving continuous administration of steroids
- Patients who have experienced serious drug allergy in the past
- Others, patients judged by the investigator or subinvestigator to be inappropriate as subject
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
TS-1 Group: The group treated with TS-1 mono-therapy
|
From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle.
Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle.
Number of Cycles: 7
Other Names:
|
Experimental: 2
TS-1+PSK Group: The group treated with combination therapy using TS-1 and PSK
|
From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle.
Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle.
Number of Cycles: 7
Other Names:
From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time of recurrence (calculation of 3-year disease-free survival and overall survival rates)
Time Frame: Five years after surgery
|
Five years after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relations of survival rate with compliance, postoperative complication, QOL, adverse events, recurrence status, and expression of immune or tumor markers
Time Frame: Five years after surgery
|
Five years after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Koichi Miwa, MD, PhD, Hokuriku-Kinki Immunochemotherapy Study Group
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994 May 7;343(8906):1122-6. doi: 10.1016/s0140-6736(94)90233-x.
- Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H, Tani T, Kaji M, Yamagishi H, Miwa K; Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol. 2006 Aug;36(8):519-22. doi: 10.1093/jjco/hyl048. Epub 2006 Jun 27.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2005
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
February 1, 2016
Study Registration Dates
First Submitted
September 18, 2005
First Submitted That Met QC Criteria
September 20, 2005
First Posted (Estimate)
September 22, 2005
Study Record Updates
Last Update Posted (Estimate)
June 7, 2016
Last Update Submitted That Met QC Criteria
June 6, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Protective Agents
- Adjuvants, Immunologic
- Antibiotics, Antineoplastic
- Interferon Inducers
- Radiation-Protective Agents
- Tegafur
- polysaccharide-K
Other Study ID Numbers
- HKIT-GC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Tegafur-gimeracil-oteracil potassium (TS-1)
-
Cancer Institute and Hospital, Chinese Academy...Chinese PLA General Hospital; Peking University Cancer Hospital & Institute; Tianjin... and other collaboratorsUnknown
-
Taiho Oncology, Inc.TerminatedMetastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal JunctionBelgium, Spain, United States, Italy, Estonia, Russian Federation, Bulgaria, Hungary, Croatia, Israel, Mexico, Poland, Portugal, Romania, South Africa, Ukraine, United Kingdom, Brazil, Germany, Argentina
-
Chinese PLA General HospitalUnknownUnresectable Pancreatic CancerChina
-
National Taiwan University HospitalTTY BiopharmUnknownPancreatic Ductal Adenocarcinoma
-
Kangbuk Samsung HospitalTerminatedStomach CancerKorea, Republic of
-
Eastern Network of Cancer Immunological Therapy...Terminated
-
Andrew KoEli Lilly and Company; Taiho Pharmaceutical Co., Ltd.TerminatedPancreatic CancerUnited States
-
Yokohama City UniversityUnknown
-
Sun Yat-sen UniversityXiangya Hospital of Central South University; Wuhan University; Zhujiang Hospital and other collaboratorsRecruitingLocally Advanced Esophageal Squamous Cell CarcinomaChina
-
Tokyo Metropolitan Oncology GroupUnknown